Citius Pharmaceuticals (CTXR) 10-Q 11 Aug 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Jun. 30, 2022	Aug. 10, 2022
Document Information Line Items
Entity Registrant Name	Citius Pharmaceuticals, Inc.
Trading Symbol	CTXR
Document Type	10-Q
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		146,129,630
Amendment Flag	false
Entity Central Index Key	0001506251
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38174
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	27-3425913
Entity Address, Address Line One	11 Commerce Drive
Entity Address, Address Line Two	First Floor
Entity Address, City or Town	Cranford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07016
City Area Code	(908)
Local Phone Number	967-6677
Title of 12(b) Security	Common stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Current Assets:
Cash and cash equivalents	$ 48,044,194	$ 70,072,946
Prepaid expenses	2,790,319	2,741,404
Total Current Assets	50,834,513	72,814,350
Property and equipment, net	4,831	7,023
Operating lease right-of-use asset, net	691,593	822,828
Other Assets:
Deposits	38,062	38,062
In-process research and development	59,400,000	59,400,000
Goodwill	9,346,796	9,346,796
Total Other Assets	68,784,858	68,784,858
Total Assets	120,315,795	142,429,059
Current Liabilities:
Accounts payable	1,690,520	1,277,095
Accrued expenses	1,301,199	621,960
Accrued compensation	1,277,501	1,906,000
Operating lease liability	191,902	177,237
Total Current Liabilities	4,461,122	3,982,292
Deferred tax liability	4,985,800	4,985,800
Operating lease liability – noncurrent	532,883	678,234
Total Liabilities	9,979,805	9,646,326
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 146,129,630 and 145,979,429 shares issued and outstanding at June 30, 2022 and September 30, 2021, respectively	146,129	145,979
Additional paid-in capital	231,287,208	228,084,195
Accumulated deficit	(121,697,727)	(96,047,821)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity	109,735,610	132,182,353
Non-controlling interest	600,380	600,380
Total Equity	110,335,990	132,782,733
Total Liabilities and Equity	$ 120,315,795	$ 142,429,059

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Sep. 30, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	146,129,630	145,979,429
Common stock, shares outstanding	146,129,630	145,979,429

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues
Operating Expenses
Research and development	4,888,192	2,203,748	13,798,251	9,946,268
General and administrative	3,024,783	3,407,088	9,038,949	7,389,269
Stock-based compensation – general and administrative	1,003,677	373,570	2,929,279	993,114
Total Operating Expenses	8,916,652	5,984,406	25,766,479	18,328,651
Operating Loss	(8,916,652)	(5,984,406)	(25,766,479)	(18,328,651)
Other Income (Expense)
Interest income	53,020	103,413	116,573	186,224
Other income		59,917		59,917
Interest expense		(2,932)		(10,839)
Total Other Income, Net	53,020	160,398	116,573	235,302
Net Loss	(8,863,632)	(5,824,008)	(25,649,906)	(18,093,349)
Deemed dividend on warrant extension		1,450,876		1,450,876
Net Loss Applicable to Common Stockholders	$ (8,863,632)	$ (7,274,884)	$ (25,649,906)	$ (19,544,225)
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share)	$ (0.06)	$ (0.05)	$ (0.18)	$ (0.2)
Weighted Average Common Shares Outstanding
Basic (in Shares)	146,129,630	137,151,269	146,061,108	96,002,039

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net Loss Per Share Applicable to Common Stockholders - Diluted	$ (0.06)	$ (0.05)	$ (0.18)	$ (0.20)
Diluted	146,129,630	137,151,269	146,061,108	96,002,039

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total Citius Pharmaceuticals, Inc. Shareholder’s Equity	Non-Controlling Interest	Total
Balance at Sep. 30, 2020		$ 55,577	$ 104,208,958	$ (70,593,867)	$ 33,670,668		$ 33,670,668
Balance (in Shares) at Sep. 30, 2020		55,576,996
Issuance of NoveCite common stock			1,799,640	(2,399,520)	(599,880)	600,380	500
Stock-based compensation expense			276,582		276,582		276,582
Net loss				(8,146,909)	(8,146,909)		(8,146,909)
Balance at Dec. 31, 2020		$ 55,577	106,285,180	(81,140,296)	25,200,461	600,380	25,800,841
Balance (in Shares) at Dec. 31, 2020		55,576,996
Issuance of common stock in private placement offering, net of costs of $1,549,602		$ 15,456	18,434,954		18,450,410		18,450,410
Issuance of common stock in private placement offering, net of costs of $1,549,602 (in Shares)		15,455,960
Issuance of common stock in registered direct offering, net of costs of $5,520,160		$ 50,830	70,929,012		70,979,842		70,979,842
Issuance of common stock in registered direct offering, net of costs of $5,520,160 (in Shares)		50,830,566
Issuance of common stock upon exercise of warrants		$ 12,788	14,229,755		14,242,543		14,242,543
Issuance of common stock upon exercise of warrants (in Shares)		12,787,697
Issuance of common stock for services		$ 50	67,950		68,000		68,000
Issuance of common stock for services (in Shares)		50,000
Stock-based compensation expense			342,962		342,962		342,962
Net loss				(4,122,432)	(4,122,432)		(4,122,432)
Balance at Mar. 31, 2021		$ 134,701	210,289,813	(85,262,728)	125,161,786	600,380	125,762,166
Balance (in Shares) at Mar. 31, 2021		134,701,219
Issuance of common stock upon exercise of warrants		$ 11,208	16,876,383		16,887,591		16,887,591
Issuance of common stock upon exercise of warrants (in Shares)		11,208,210
Issuance of common stock upon exercise of stock options		$ 70	82,564		82,634		82,634
Issuance of common stock upon exercise of stock options (in Shares)		70,000
Stock-based compensation expense			373,570		373,570		373,570
Net loss				(5,824,008)	(5,824,008)		(5,824,008)
Balance at Jun. 30, 2021		$ 145,979	227,622,330	(91,086,736)	136,681,573	600,380	137,281,953
Balance (in Shares) at Jun. 30, 2021		145,979,429
Balance at Sep. 30, 2021		$ 145,979	228,084,195	(96,047,821)	132,182,353	600,380	132,782,733
Balance (in Shares) at Sep. 30, 2021		145,979,429
Issuance of common stock for services		$ 50	95,834		95,884		95,884
Issuance of common stock for services (in Shares)		50,201
Stock-based compensation expense			904,604		904,604		904,604
Net loss				(9,225,220)	(9,225,220)		(9,225,220)
Balance at Dec. 31, 2021		$ 146,029	229,084,633	(105,273,041)	123,957,621	600,380	124,558,001
Balance (in Shares) at Dec. 31, 2021		146,029,630
Issuance of common stock for services		$ 100	177,900		178,000		178,000
Issuance of common stock for services (in Shares)		100,000
Stock-based compensation expense			1,020,998		1,020,998		1,020,998
Net loss				(7,561,054)	(7,561,054)		(7,561,054)
Balance at Mar. 31, 2022		$ 146,129	230,283,531	(112,834,095)	117,595,565	600,380	118,195,945
Balance (in Shares) at Mar. 31, 2022		146,129,630
Stock-based compensation expense			1,003,677		1,003,677		1,003,677
Net loss				(8,863,632)	(8,863,632)		(8,863,632)
Balance at Jun. 30, 2022		$ 146,129	$ 231,287,208	$ (121,697,727)	$ 109,735,610	$ 600,380	$ 110,335,990
Balance (in Shares) at Jun. 30, 2022		146,129,630

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of common stock in private placement offering, net of costs	$ 1,549,602
Issuance of common stock in registered direct offering, net of costs	$ 5,520,160

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows From Operating Activities:
Net loss	$ (25,649,906)	$ (18,093,349)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,929,279	993,114
Issuance of common stock for services	273,884	68,000
Amortization of operating lease right-of-use asset	131,235	121,339
Depreciation	2,192	761
Changes in operating assets and liabilities:
Prepaid expenses	(48,915)	(1,149,158)
Deposits		19,031
Accounts payable	413,425	(501,571)
Accrued expenses	679,239	202,696
Accrued compensation	(628,499)	(115,106)
Accrued interest		(87,996)
Operating lease liability	(130,686)	(117,145)
Net Cash Used In Operating Activities	(22,028,752)	(18,659,384)
Cash Flows From Investing Activities:
Purchase of property and equipment		(6,938)
Net Cash Used In Investing Activities		(6,938)
Cash Flows From Financing Activities:
Principal paid on notes payable – related parties		(172,970)
Proceeds from sale of NoveCite, Inc. common stock		500
Net proceeds from private placement		18,450,410
Net proceeds from registered direct offering		70,979,842
Net proceeds from common stock warrant exercises		31,130,134
Net proceeds from common stock option exercises		82,634
Net Cash Provided By Financing Activities		120,470,550
Net Change in Cash and Cash Equivalents	(22,028,752)	101,804,228
Cash and Cash Equivalents - Beginning of Period	70,072,946	13,859,748
Cash and Cash Equivalents - End of Period	$ 48,044,194	$ 115,663,976

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Citius Pharmaceuticals, Inc. (“Citius,” the “Company,” “we” or “us”) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy. On March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary by issuing shares of its common stock. On September 11, 2020, we formed NoveCite, Inc. (“NoveCite”), a Delaware corporation, of which we own 75% (7,500,000 shares) of the issued and outstanding capital stock (see Note 3). On August 23, 2021, we formed Citius Acquisition Corp., as a wholly-owned subsidiary in conjunction with the acquisition of I/ONTAK (formerly E7777). Citius Acquisition Corp. was inactive until April 1, 2022 when it assumed the development of I/ONTAK. In-process research and development (“IPR&D”) consists of (i) the $19,400,000 acquisition value of LMB’s leading drug candidate (Mino-Lok), which is an antibiotic solution used to treat catheter-related bloodstream infections and is expected to be amortized on a straight-line basis over a period of eight years commencing upon revenue generation, and (ii) the $40,000,000 acquisition value of the exclusive license for I/ONTAK (denileukin diftitox), which is a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma, and is expected to be amortized on a straight-line basis over a period of twelve years commencing upon revenue generation. Goodwill of $9,346,796 represents the value of LMB’s industry relationships and its assembled workforce. Goodwill will not be amortized but will be tested at least annually for impairment. Citius is subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by Citius or its competitors of research and development stage product candidates, market acceptance of its product candidates that might be approved, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company’s ability to obtain additional financing and the Company’s compliance with governmental and other regulations. Basis of Presentation and Summary of Significant Accounting Policies Basis of Preparation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of June 30, 2022, and the results of its operations and cash flows for the three and nine month periods ended June 30, 2022 and 2021. The operating results for the three- and nine-month periods ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2021 filed with the Securities and Exchange Commission. Use of Estimates Basic and Diluted Net Loss per Common Share Recently Issued Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities.

Liquidity and Management_s Plan

Liquidity and Management’s Plan	9 Months Ended
	Jun. 30, 2022
Liquidity and Managements Plan [Abstract]
LIQUIDITY AND MANAGEMENT’S PLAN	2. LIQUIDITY AND MANAGEMENT’S PLAN The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company experienced negative cash flows from operations of $22,028,752 for the nine months ended June 30, 2022. As a result of the Company’s common stock offerings and common stock warrant exercises during the year ended September 30, 2021, the Company had working capital of approximately $46,400,000 at June 30, 2022. The Company estimates that its available cash resources will be sufficient to fund its operations through August 2023. The Company has generated no operating revenue to date and has principally raised capital through the issuance of debt and equity instruments to finance its operations. The Company’s continued operations beyond August 2023, including its development plans for Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK, will depend on its ability to obtain regulatory approval to market Mino-Lok and/or I/ONTAK and generate substantial revenue from the sale of Mino-Lok and/or I/ONTAK and on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships, or out-licensing of its product candidates. However, the Company can provide no assurances on regulatory approval, commercialization or future sales of Mino-Lok or I/ONTAK or that financing or strategic relationships will be available on acceptable terms, or at all. If the Company is unable to raise sufficient capital, find strategic partners or generate substantial revenue from the sale of Mino-Lok or I/ONTAK, there would be a material adverse effect on its business. Further, the Company expects to incur additional expenses as it continues to develop its product candidates, including seeking regulatory approval, and protecting its intellectual property.

Patent and Technology License A

Patent and Technology License Agreements	9 Months Ended
	Jun. 30, 2022
Patent and Technology License Agreement [Abstract]
PATENT AND TECHNOLOGY LICENSE AGREEMENTS	3. PATENT AND TECHNOLOGY LICENSE AGREEMENTS Patent and Technology License Agreement – Mino-Lok LMB has a patent and technology license agreement with Novel Anti-Infective Therapeutics, Inc. (“NAT”) to develop and commercialize Mino-Lok® on an exclusive, worldwide sub licensable basis, as amended. LMB pays an annual maintenance fee each June until commercial sales of a product subject to the license commence. The Company recorded an annual maintenance fee of $90,000 in June 2022 and 2021. LMB will also pay annual royalties on net sales of licensed products, with royalties ranging from the mid-single digits to the low double digits. In limited circumstances in which the licensed product is not subject to a valid patent claim and a competitor is selling a competing product, the royalty rate is in the low- to mid-single digits. After a commercial sale is obtained, LMB must pay minimum aggregate annual royalties of $100,000 in the first commercial year which is prorated for a less than 12-month period, increasing $25,000 per year to a maximum of $150,000 annually. LMB must also pay NAT up to an aggregate of $1,100,000 upon achieving specified regulatory and sales milestones. Finally, LMB must pay NAT a specified percentage of payments received from any sub-licensees. Unless earlier terminated by NAT, based on the failure to achieve certain development and commercial milestones, the license agreement remains in effect until the date that all patents licensed under the agreement have expired and all patent applications within the licensed patent rights have been cancelled, withdrawn or expressly abandoned. Patent and Technology License Agreement – Mino-Wrap On January 2, 2019, we entered into a patent and technology license agreement with the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson Cancer Center (“Licensor”), whereby we in-licensed exclusive worldwide rights to the patented technology for any and all uses relating to breast implants. We intend to develop a liquefying gel-based wrap containing minocycline and rifampin for the reduction of infections associated with breast implants following breast reconstructive surgeries (“Mino-Wrap”). We are required to use commercially reasonable efforts to commercialize Mino-Wrap under several regulatory scenarios and achieve milestones associated with these regulatory options leading to an approval from the U.S. Food and Drug Administration (“FDA”). Under the license agreement, the Company paid an annual maintenance fee of $60,000 and $45,000 in January 2022 and 2021, respectively. The annual maintenance fee increases by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term. We will be responsible for all patent expenses incurred by Licensor for the term of the agreement although Licensor is responsible for filing, prosecution and maintenance of all patents. Unless earlier terminated by Licensor, based upon the failure by us to achieve certain development and commercial milestones or for various breaches by us, the agreement expires on the later of the expiration of the patents or January 2, 2034. License Agreement with Novellus On March 31, 2020, we entered into an option agreement with a subsidiary of Novellus, Inc. (“Novellus”) to in-license from Novellus on a worldwide basis, a novel cellular therapy for acute respiratory distress syndrome (“ARDS”). Our Board Chairman Leonard Mazur, who is also our largest stockholder, was at the time a significant shareholder of Novellus and subsequent to the option agreement and the license agreement discussed below, became a director of Novellus. As required by our Code of Ethics, the Audit Committee of our Board of Directors approved the entry into the option agreement with Novellus, as did the disinterested members of our Board of Directors. On October 6, 2020, our subsidiary, NoveCite, exercised the option and signed an exclusive license agreement with Novellus. Upon execution of the agreement, we paid $5,000,000 to Novellus, which was charged to research and development expense in the three-month period ended December 31, 2020, and issued Novellus shares of NoveCite’s common stock representing 25% of the outstanding equity. We own the other 75% of NoveCite’s outstanding equity. Pursuant to the terms of the stock subscription agreement between Novellus and NoveCite, if NoveCite issued additional equity, subject to certain exceptions, NoveCite had to maintain Novellus’s ownership at 25% by issuing additional shares to Novellus. Citius is responsible for the operational activities of NoveCite, and bears all costs necessary to operate NoveCite. Citius’s officers are also the officers of NoveCite and oversee the business strategy and operations of NoveCite. As such, NoveCite is accounted for as a consolidated subsidiary with a noncontrolling interest. Novellus has no contractual rights in the profits or obligations to share in the losses of NoveCite, and the Company has not allocated any losses to the noncontrolling interest. NoveCite is obligated to pay Novellus up to an aggregate of $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) the date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Novellus an amount equal to a mid-twenties percentage of any sublicensee fees it receives. Under the terms of the license agreement, in the event that Novellus receives any revenue involving the original cell line included in the licensed technology, then Novellus shall remit to NoveCite 50% of such revenue. The term of the license agreement will continue on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire royalty term. Either party may terminate the license agreement upon written notice if the other party is in material default. NoveCite may terminate the license agreement at any time without cause upon 90 days prior written notice. Novellus will be responsible for preparing, filing, prosecuting and maintaining all patent applications and patents included in the licensed patents in the territory, provided however, that if Novellus decides that it is not interested in maintaining a particular licensed patent or in preparing, filing, or prosecuting a licensed patent, NoveCite will have the right, but not the obligation, to assume such responsibilities in the territory at NoveCite’s sole cost and expense. In July 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). In connection with that transaction, the stock subscription agreement between Novellus and NoveCite was amended to assign to Brooklyn all of Novellus’s right, title, and interest in the stock subscription agreement and delete the anti-dilution protection and replace it with a right of first refusal whereby Brooklyn will have the right to purchase all or a portion of the securities that NoveCite intends to sell or in the alternative, at the option of NoveCite, Brooklyn may purchase that amount of the securities proposed to be sold by NoveCite to allow Brooklyn to maintain its then percentage ownership. License Agreement with Eisai In September 2021, the Company entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), to acquire its exclusive license of I/ONTAK (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. Under the terms of this agreement, Citius acquired Dr. Reddy's exclusive license of I/ONTAK from Eisai Co., Ltd. ("Eisai") and other related assets owned by Dr. Reddy's. Citius's exclusive license includes rights to develop and commercialize I/ONTAK in all markets except for Japan and certain parts of Asia. Additionally, Citius retained an option on the right to develop and market the product in India. Eisai retains exclusive development and marketing rights for the agent in Japan and Asia. Citius paid a $40 million upfront payment which represents the acquisition date fair value of the in-process research and development acquired from Dr. Reddy’s. Dr. Reddy’s is entitled to up to an aggregate of $40 million in development milestone payments related to CTCL approvals in the U.S. and other markets, up to an aggregate of $70 million in development milestones for additional indications, as well as commercial milestone payments and low double-digit tiered royalties on net product sales, and up to an aggregate of $300 million for commercial sales milestones. We also must pay on a fiscal quarter basis tiered royalties equal to low double-digit percentages of net product sales. The royalties will end on the earlier of (i) the 15-year anniversary of the first commercial sale of the latest indication that received regulatory approval in the applicable country and (ii) the date on which a biosimilar product results in the reduction of net sales in the applicable product by 50% in two consecutive quarters, as compared to the four quarters prior to the first commercial sale of the biosimilar product. We will also pay to Dr. Reddy’s an amount equal to a low-thirties percentage of any sublicense upfront consideration or milestone payments (or the like) received by us and the greater of (i) a low-thirties percentage of any sublicensee sales-based royalties or (ii) a mid-single digit percentage of such licensee’s net sales. Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7.0 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and up to an aggregate of $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a BLA for I/ONTAK. Eisai will be responsible for completing the current CTCL clinical trial, and chemistry, manufacturing and controls activities through the filing of a BLA for I/ONTAK with the FDA. Citius will be responsible for development costs associated with potential additional indications. The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, until the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million. Either party may terminate the license agreement upon written notice if the other party is in material breach of the agreement, subject to cure within the designated time periods. Either party also may terminate the license agreement immediately upon written notice if the other party files for bankruptcy or takes related actions or is unable to pay its debts as they become due. Additionally, either party will have the right to terminate the agreement if the other party directly or indirectly challenges the patentability, enforceability or validity of any licensed patent. Also under the agreement with Dr. Reddy’s, we are required to (i) use commercially reasonable efforts to make commercially available products in the CTCL indication, peripheral T-cell lymphoma indication and immuno-oncology indication, (ii) initiate two investigator initiated immuno-oncology trials, (iii) use commercially reasonable efforts to achieve each of the approval milestones, and (iv) complete each specified immuno-oncology investigator trial on or before the four-year anniversary of the effective date of the definitive agreement. Additionally, we are required to commercially launch a product in a territory within six months of receiving regulatory approval for such product in each such jurisdiction.

Notes Payable

Notes Payable	9 Months Ended
	Jun. 30, 2022
Notes Payable [Abstract]
NOTES PAYABLE	4. NOTES PAYABLE Notes Payable – Related Parties Prior to June 30, 2021, we had outstanding notes payable held by our Chairman, Leonard Mazur, in the amount of $160,470 and notes payable held by our then Chief Executive Officer, Myron Holubiak, in the amount of $12,500. Notes with a principal balance of $104,000 accrued interest at the prime rate plus 1.0% per annum and notes with a principal balance of $68,970 accrued interest at 12% per annum. In June 2021, we repaid the $172,970 principal balance of these notes and paid accrued interest of $38,917. Accrued interest of $59,917 was forgiven and was recorded as other income in the three and nine months ended June 30, 2021. Interest expense on notes payable – related parties was $2,509 and $9,605 for the three and nine months ended June 30, 2021, respectively. Paycheck Protection Program On April 12, 2020, the Company applied for a forgivable loan through the Small Business Association’s Paycheck Protection Program (the “PPP”). The loan accrued interest at a rate of 1% and was forgivable if it was used to pay qualifying costs such as payroll, rent and utilities. On April 15, 2020, the Company received $164,583 from the PPP. On July 28, 2021, the Small Business Administration gave full forgiveness of the PPP loan and the Company recorded a gain from debt extinguishment of $166,557 consisting of the principal balance and related accrued interest expense. Interest expense was $423 and $1,234 for the three and nine months ended June 30, 2021, respectively.

Common Stock, Stock Options and

Common Stock, Stock Options and Warrants	9 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
COMMON STOCK, STOCK OPTIONS AND WARRANTS	5. COMMON STOCK, STOCK OPTIONS AND WARRANTS Authorized Common Stock On June 21, 2021, our stockholders approved an amendment to our Articles of Incorporation to increase the authorized number of shares of capital stock from 210,000,000 to 410,000,000 and the authorized number of common shares from 200,000,000 to 400,000,000. Common Stock Offerings On January 27, 2021, the Company closed a private placement for 15,455,960 common shares and warrants to purchase 7,727,980 common shares, at a purchase price of $1.294 per common share and accompanying warrant, for gross proceeds of $20,000,012. The 7,727,980 warrants are immediately exercisable at $1.231 per common share for a term of five and one-half years. The Company paid the placement agent a fee of 7% of the gross proceeds totaling $1,400,001 and issued the placement agent 1,081,917 immediately exercisable warrants at $1.6175 per common share for a term of five and one-half years. The Company also reimbursed the placement agent for $85,000 in expenses and incurred $64,601 in other expenses. Net proceeds from the offering were $18,450,410. The estimated fair value of the 7,727,980 warrants issued to the investors was approximately $7,582,000 and the estimated fair value of the 1,081,917 warrants issued to the placement agent was approximately $1,025,000. On February 19, 2021, the Company closed a registered direct offering for 50,830,566 common shares and warrants to purchase up to 25,415,283 common shares, at a purchase price of $1.505 per share of common stock and accompanying warrant, for gross proceeds of $76,500,002. The 25,415,283 warrants are immediately exercisable at $1.70 per common share for a term of five years. The Company paid the placement agent a fee of 7% of the gross proceeds totaling $5,355,000 and issued the placement agent 3,558,140 immediately exercisable warrants at $1.881 per common share for a term of five years. The Company also reimbursed the placement agent for $85,000 in expenses and incurred $80,160 in other expenses. Net proceeds from the offering were $70,979,842. The estimated fair value of the 25,415,283 warrants issued to the investors was approximately $42,322,000 and the estimated fair value of the 3,558,140 warrants issued to the placement agent was approximately $5,850,000. Common Stock Issued for Services On November 2, 2021, the Company issued 50,201 shares of common stock for investor relations services and expensed the $95,884 fair value of the common stock issued. On March 21, 2022, the Company issued 100,000 shares of common stock for media, public and investor relations services and expensed the $178,000 fair value of the common stock issued. Stock Option Plans Pursuant to our 2014 Stock Incentive Plan, we reserved 866,667 common shares for issuance to employees, directors and consultants. As of June 30, 2022, options to purchase 855,171 shares were outstanding and no shares remain available for future grants. On February 7, 2018, our stockholders approved the 2018 Omnibus Stock Incentive Plan and we reserved 2,000,000 common shares for issuance to employees, directors and consultants. As of June 30, 2022, options to purchase 1,820,000 shares were outstanding and no shares remain available for future grants. On February 10, 2020, our stockholders approved the 2020 Stock Plan and we reserved 3,110,000 common shares for issuance to employees, directors, and consultants. As of June 30, 2022, options to purchase 1,870,000 shares were outstanding and the remaining 1,240,000 shares were transferred to the 2021 Omnibus Stock Incentive Plan (“2021 Stock Plan”). On May 24, 2021, our stockholders approved the 2021 Stock Plan and we reserved 8,740,000 shares for issuance to employees, directors, and consultants through options, SARs, dividend equivalent rights, restricted stock, restricted stock units, or other rights. As of June 30, 2022, options to purchase 4,855,000 shares were outstanding and there were 3,885,000 shares available for future grants. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The expected term of stock options granted, all of which qualify as “plain vanilla,” is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. A summary of option activity under our stock option plans (excluding the NoveCite Stock Plan) is presented below: Option Weighted- Weighted- Aggregate Outstanding at October 1, 2021 5,755,171 $ 2.13 8.02 years $ 3,589,392 Granted 3,645,000 1.97 Exercised — — Forfeited or expired — — Outstanding at June 30, 2022 9,400,171 $ 2.07 8.06 years $ 302,939 Exercisable at June 30, 2022 3,675,742 $ 2.48 6.56 years $ 236,478 On October 11, 2021, the Board of Directors granted options to purchase 2,515,000 shares to employees, 375,000 shares to directors and 175,000 shares to consultants at $2.04 per share. On November 1, 2021, the Board of Directors granted options to purchase 200,000 shares to an employee at $1.87 per share. During January and February 2022, options to purchase 300,000 shares were granted to three new employees at exercise prices ranging from $1.44 to $1.49 per share. In April and June 2022, options to purchase 80,000 shares were granted to two new employees at exercise prices ranging from $0.90 to $1.47 per share. The weighted average grant date fair value of the options granted during the nine months ended June 30, 2022 was estimated at $1.67 per share. All of these options vest over terms of 12 to 36 months and have a term of 10 years. On October 6, 2020, the Board of Directors granted stock options to purchase a total of 800,000 shares to employees, 175,000 shares to directors and 125,000 shares to consultants at $1.01 per share. On February 16, 2021, the Board of Directors granted stock options to purchase a total of 125,000 shares to directors at $1.69 per share. On June 10, 2021, the Board of Directors granted stock options to purchase 100,000 shares to employees and 10,000 shares to a consultant at $2.50 per share. The weighted average grant date fair value of the options granted during the nine months ended June 30, 2021 was estimated at $1.03 per share. All of these options vest over terms of 12 to 36 months and have a term of 10 years. Stock-based compensation expense for the three months ended June 30, 2022 and 2021 was $1,003,677 (including $33,333 for the NoveCite Stock Plan) and $373,570 (including $18,833 for the NoveCite Stock Plan), respectively. Stock-based compensation expense for the nine months ended June 30, 2022 and 2021 was $2,929,279 (including $99,999 for the NoveCite Stock Plan) and $993,114 (including $50,222 for the NoveCite Stock Plan), respectively. At June 30, 2022, unrecognized total compensation cost related to unvested awards under the Citius stock plans of $6,261,023 is expected to be recognized over a weighted average period of 2.1 years. On November 5, 2020, the stockholders of NoveCite, approved NoveCite’s Stock Plan and we reserved 2,000,000 common shares of NoveCite for issuance. The NoveCite Stock Plan provides incentives to employees, directors, and consultants through grants of options, SARs, dividend equivalent rights, restricted stock, restricted stock units, or other rights. As of June 30, 2022, there were options outstanding to purchase 2,000,000 common shares of NoveCite and no shares available for future grants. As of June 30, 2022, NoveCite has options outstanding to purchase 2,000,000 common shares at a weighted average exercise price of $0.24 per share, of which 376,665 are exercisable. All of these options vest over 36 months and have a term of 10 years. The weighted average remaining contractual term of options outstanding under the NoveCite Stock Plan is 8.7 years. At June 30, 2022, unrecognized total compensation cost related to unvested awards under the NoveCite Stock Plan of $216,444 is expected to be recognized over a weighted average period of 1.7 years. Warrants As of June 30, 2022, we have reserved shares of common stock for the exercise of outstanding warrants as follows: Exercise Number Expiration Date 2017 Public Offering Investors $ 4.13 1,622,989 August 8, 2022 2017 Public Offering Underwriter 4.54 65,940 February 2, 2023 December 2017 Registered Direct/Private Placement Offering Investors 4.63 640,180 June 19, 2023 December 2017 Registered Direct/Private Placement Offering Placement Agent 5.87 89,625 December 19, 2022 March 2018 Registered Direct/Private Placement Offering Investors 2.86 218,972 October 2, 2023 March 2018 Registered Direct/Private Placement Offering Placement Agent 3.73 46,866 March 28, 2023 August 2018 Offering Investors 1.15 3,921,569 August 14, 2023 August 2018 Offering Agent 1.59 189,412 August 8, 2023 April 2019 Registered Direct/Private Placement Offering Investors 1.42 1,294,498 April 5, 2024 April 2019 Registered Direct/Private Placement Offering Placement Agent 1.93 240,130 April 5, 2024 September 2019 Offering Investors 0.77 2,793,297 September 27, 2024 September 2019 Offering Underwriter 1.12 194,358 September 27, 2024 February 2020 Exercise Agreement Placement Agent 1.28 138,886 August 19, 2025 May 2020 Registered Direct Offering Investors 1.00 1,670,588 November 18, 2025 May 2020 Registered Direct Offering Placement Agent 1.33 155,647 May 14, 2025 August 2020 Underwriter 1.31 201,967 August 10, 2025 January 2021 Private Placement Offering Investors 1.23 3,091,192 July 27, 2026 January 2021 Private Placement Offering Agent 1.62 351,623 July 27, 2026 February 2021 Registered Direct Offering Investors 1.70 20,580,283 February 19, 2026 February 2021 Registered Direct Offering Agent 1.88 2,506,396 February 19, 2026 40,014,418 In April 2021, we extended the term by three years to April 5, 2024 for 1,294,498 warrants for common stock with an exercise price of $1.42 per share and 240,130 warrants with an exercise price of $1.93 per share. We recorded a deemed dividend of $1,450,876 based on the excess of the fair value of the modified warrants over the fair value of the warrants before the modification, the effect of which was an increase in the net loss attributable to common shareholders in the statement of operations for the three and nine months ended June 30, 2021. At June 30, 2022, the weighted average remaining life of the outstanding warrants is 3.0 years, all warrants are exercisable, and the aggregate intrinsic value of the warrants outstanding was $418,995. Common Stock Reserved A summary of common stock reserved for future issuances as of June 30, 2022 is as follows: Stock plan options outstanding 9,400,171 Stock plan shares available for future grants 3,885,000 Warrants outstanding 40,014,418 Total 53,299,589

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS The Company had outstanding debt due to Leonard Mazur (Chairman of the Board) and Myron Holubiak (then Chief Executive Officer) (see Note 4). Leonard Mazur was a director and significant shareholder of Novellus until July 2021. On October 6, 2020, the Company, through its subsidiary NoveCite, entered into an exclusive agreement with Novellus to develop cellular therapies (see Note 3). In April 2021, we extended the term by three years for 1,294,498 warrants held by our Chairman and our Chief Executive Officer (see Note 5).

Operating Lease

Operating Lease	9 Months Ended
	Jun. 30, 2022
Operating Lease [Abstract]
OPERATING LEASE	7. OPERATING LEASE Effective July 1, 2019, Citius entered into a 76-month lease for office space in Cranford, NJ. Citius pays its proportionate share of real estate taxes and operating expenses in excess of the base year expenses. These costs are considered to be variable lease payments and are not included in the determination of the lease’s right-of-use asset or lease liability. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company’s lease does not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments based on the remaining lease term as of the adoption date. ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. ● The expected lease terms include noncancelable lease periods. The elements of lease expense are as follows: Lease cost Nine Months Nine Months Operating lease cost $ 179,116 $ 179,118 Variable lease cost 772 194 Total lease cost $ 179,888 $ 179,312 Other information Weighted-average remaining lease term - operating leases 3.3 Years 4.3 Years Weighted-average discount rate - operating leases 8.0 % 8.0 % Maturities of lease liabilities due under the Company’s non-cancellable leases as of June 30, 2022 is as follows: Year Ending September 30, June 30, 2022 (excluding the 9 months ended June 30, 2022) $ 60,737 2023 244,165 2024 249,024 2025 253,883 2026 21,460 Total lease payments 829,269 Less: interest (104,484 ) Present value of lease liabilities $ 724,785 Leases Classification June 30, September 30, Assets Lease asset Operating $ 691,593 $ 822,828 Total lease assets $ 691,593 $ 822,828 Liabilities Current Operating $ 191,902 $ 177,237 Non-current Operating 532,883 678,234 Total lease liabilities $ 724,785 $ 855,471 Interest expense on the lease liability was $47,881 and $57,779 for the nine months ended June 30, 2022 and 2021, respectively.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of June 30, 2022, and the results of its operations and cash flows for the three and nine month periods ended June 30, 2022 and 2021. The operating results for the three- and nine-month periods ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2021 filed with the Securities and Exchange Commission.
Use of Estimates	Use of Estimates
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities.

Common Stock, Stock Options a_2

Common Stock, Stock Options and Warrants (Tables)	9 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of option activity under the plans	Option Weighted- Weighted- Aggregate Outstanding at October 1, 2021 5,755,171 $ 2.13 8.02 years $ 3,589,392 Granted 3,645,000 1.97 Exercised — — Forfeited or expired — — Outstanding at June 30, 2022 9,400,171 $ 2.07 8.06 years $ 302,939 Exercisable at June 30, 2022 3,675,742 $ 2.48 6.56 years $ 236,478
Schedule of warrants outstanding	Exercise Number Expiration Date 2017 Public Offering Investors $ 4.13 1,622,989 August 8, 2022 2017 Public Offering Underwriter 4.54 65,940 February 2, 2023 December 2017 Registered Direct/Private Placement Offering Investors 4.63 640,180 June 19, 2023 December 2017 Registered Direct/Private Placement Offering Placement Agent 5.87 89,625 December 19, 2022 March 2018 Registered Direct/Private Placement Offering Investors 2.86 218,972 October 2, 2023 March 2018 Registered Direct/Private Placement Offering Placement Agent 3.73 46,866 March 28, 2023 August 2018 Offering Investors 1.15 3,921,569 August 14, 2023 August 2018 Offering Agent 1.59 189,412 August 8, 2023 April 2019 Registered Direct/Private Placement Offering Investors 1.42 1,294,498 April 5, 2024 April 2019 Registered Direct/Private Placement Offering Placement Agent 1.93 240,130 April 5, 2024 September 2019 Offering Investors 0.77 2,793,297 September 27, 2024 September 2019 Offering Underwriter 1.12 194,358 September 27, 2024 February 2020 Exercise Agreement Placement Agent 1.28 138,886 August 19, 2025 May 2020 Registered Direct Offering Investors 1.00 1,670,588 November 18, 2025 May 2020 Registered Direct Offering Placement Agent 1.33 155,647 May 14, 2025 August 2020 Underwriter 1.31 201,967 August 10, 2025 January 2021 Private Placement Offering Investors 1.23 3,091,192 July 27, 2026 January 2021 Private Placement Offering Agent 1.62 351,623 July 27, 2026 February 2021 Registered Direct Offering Investors 1.70 20,580,283 February 19, 2026 February 2021 Registered Direct Offering Agent 1.88 2,506,396 February 19, 2026 40,014,418
Schedule of common stock reserved for future issuances	Stock plan options outstanding 9,400,171 Stock plan shares available for future grants 3,885,000 Warrants outstanding 40,014,418 Total 53,299,589

Operating Lease (Tables)

Operating Lease (Tables)	9 Months Ended
	Jun. 30, 2022
Operating Lease [Abstract]
Schedule operating lease expense	Lease cost Nine Months Nine Months Operating lease cost $ 179,116 $ 179,118 Variable lease cost 772 194 Total lease cost $ 179,888 $ 179,312 Other information Weighted-average remaining lease term - operating leases 3.3 Years 4.3 Years Weighted-average discount rate - operating leases 8.0 % 8.0 %
Schedule of lease liabilities due under the company’s non-cancellable leases	Year Ending September 30, June 30, 2022 (excluding the 9 months ended June 30, 2022) $ 60,737 2023 244,165 2024 249,024 2025 253,883 2026 21,460 Total lease payments 829,269 Less: interest (104,484 ) Present value of lease liabilities $ 724,785
Schedule operating leases assets and liabilities	Leases Classification June 30, September 30, Assets Lease asset Operating $ 691,593 $ 822,828 Total lease assets $ 691,593 $ 822,828 Liabilities Current Operating $ 191,902 $ 177,237 Non-current Operating 532,883 678,234 Total lease liabilities $ 724,785 $ 855,471

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Jun. 30, 2022	Sep. 11, 2020
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Shares owned (in Shares)		7,500,000
Research and development	$ 19,400,000
Revenue generation	40,000,000
Goodwill	$ 9,346,796
Delaware Corporation [Member]
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Ownership, percentage		75%

Liquidity and Management_s Pl_2

Liquidity and Management’s Plan (Details)	9 Months Ended
	Jun. 30, 2022 USD ($)
Liquidity And Managements Plan [Abstract]
Negative cash flow operations	$ 22,028,752
Working capital	$ 46,400,000

Patent and Technology License_2

Patent and Technology License Agreements (Details) - USD ($)		1 Months Ended		9 Months Ended
	Oct. 06, 2020	Jan. 31, 2022	Jan. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
Patent and Technology License Agreements (Details) [Line Items]
Annual maintenance fee expense				$ 90,000	$ 90,000
Annual minimum royalty payment				100,000
Increasing annual royalties				25,000
Maximum aggregate annual royalties				150,000
Payable amount to NAT				1,100,000
Annual maintenance fee		$ 60,000	$ 45,000
Research and development expense				$ 19,400,000
Developmental milestone, description				NoveCite is obligated to pay Novellus up to an aggregate of $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) the date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Novellus an amount equal to a mid-twenties percentage of any sublicensee fees it receives.
Revenue percentage				50%
Description of license agreement				The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, until the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million.
License agreement development, description				Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7.0 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and up to an aggregate of $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a BLA for I/ONTAK.
NoveCite [Member]
Patent and Technology License Agreements (Details) [Line Items]
Research and development expense	$ 5,000,000
Outstanding equity						25%
Percentage of outstanding equity	75%
Percentage of ownership additional shares	25%
Patent and Technology [Member]
Patent and Technology License Agreements (Details) [Line Items]
Description of annual maintenance fee				The annual maintenance fee increases by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term.
Eisai [Member]
Patent and Technology License Agreements (Details) [Line Items]
Description of license agreement				Citius paid a $40 million upfront payment which represents the acquisition date fair value of the in-process research and development acquired from Dr. Reddy’s. Dr. Reddy’s is entitled to up to an aggregate of $40 million in development milestone payments related to CTCL approvals in the U.S. and other markets, up to an aggregate of $70 million in development milestones for additional indications, as well as commercial milestone payments and low double-digit tiered royalties on net product sales, and up to an aggregate of $300 million for commercial sales milestones. We also must pay on a fiscal quarter basis tiered royalties equal to low double-digit percentages of net product sales. The royalties will end on the earlier of (i) the 15-year anniversary of the first commercial sale of the latest indication that received regulatory approval in the applicable country and (ii) the date on which a biosimilar product results in the reduction of net sales in the applicable product by 50% in two consecutive quarters, as compared to the four quarters prior to the first commercial sale of the biosimilar product.

Notes Payable (Details)

Notes Payable (Details) - USD ($)		1 Months Ended		3 Months Ended	9 Months Ended
	Apr. 12, 2020	Jul. 28, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021
Notes Payable (Details) [Line Items]
Note payable, description			Notes with a principal balance of $104,000 accrued interest at the prime rate plus 1.0% per annum and notes with a principal balance of $68,970 accrued interest at 12% per annum.
Principal amount			$ 172,970	$ 172,970	$ 172,970
Accrued interest paid			38,917
Accrued interest				59,917	59,917
Interest expense on notes payable - related parties				2,509	9,605
Paycheck protection program, description	the Company applied for a forgivable loan through the Small Business Association’s Paycheck Protection Program (the “PPP”). The loan accrued interest at a rate of 1% and was forgivable if it was used to pay qualifying costs such as payroll, rent and utilities. On April 15, 2020, the Company received $164,583 from the PPP.
Gain from debt extinguishment		$ 166,557
Interest expense				$ 423	$ 1,234
Chairman [Member] | Leonard Mazur [Member]
Notes Payable (Details) [Line Items]
Notes payables			160,470
Chief Executive Officer [Member] | Myron Holubiak [Member]
Notes Payable (Details) [Line Items]
Notes payables			$ 12,500

Common Stock, Stock Options a_3

Common Stock, Stock Options and Warrants (Details) - USD ($)							1 Months Ended									3 Months Ended	9 Months Ended
	Nov. 02, 2021	Nov. 01, 2021	Oct. 11, 2021	Jun. 10, 2021	Apr. 30, 2021	Oct. 06, 2020	Jun. 30, 2022	Apr. 30, 2022	Mar. 21, 2022	Feb. 28, 2022	Jan. 31, 2022	May 24, 2021	Feb. 19, 2021	Feb. 16, 2021	Jan. 27, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 21, 2021	Mar. 31, 2021	Dec. 31, 2020	Nov. 05, 2020	Sep. 30, 2020	Sep. 11, 2020	Feb. 10, 2020	Feb. 07, 2018
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common shares authorized							400,000,000										400,000,000				400,000,000
Common stock offerings, description															the Company closed a private placement for 15,455,960 common shares and warrants to purchase 7,727,980 common shares, at a purchase price of $1.294 per common share and accompanying warrant, for gross proceeds of $20,000,012. The 7,727,980 warrants are immediately exercisable at $1.231 per common share for a term of five and one-half years. The Company paid the placement agent a fee of 7% of the gross proceeds totaling $1,400,001 and issued the placement agent 1,081,917 immediately exercisable warrants at $1.6175 per common share for a term of five and one-half years. The Company also reimbursed the placement agent for $85,000 in expenses and incurred $64,601 in other expenses. Net proceeds from the offering were $18,450,410. The estimated fair value of the 7,727,980 warrants issued to the investors was approximately $7,582,000 and the estimated fair value of the 1,081,917 warrants issued to the placement agent was approximately $1,025,000.
Issued shares									100,000
Fair value of common stock (in Dollars)									$ 178,000
Common shares reserved																									2,000,000
Option to purchase share outstanding							4,855,000										4,855,000
Remaining shares																											7,500,000
Shares available for future grants																	3,885,000
Options to purchase shares		200,000	175,000			125,000	80,000	80,000		300,000	300,000
Share price (in Dollars per share)		$ 1.87	$ 2.04			$ 1.01	$ 1.67										$ 1.67
Exercise price (in Dollars per share)					$ 1.42
Options vest over terms																	10 years
Share issued price per share																		1.03
Stock-based compensation expense description																	Stock-based compensation expense for the three months ended June 30, 2022 and 2021 was $1,003,677 (including $33,333 for the NoveCite Stock Plan) and $373,570 (including $18,833 for the NoveCite Stock Plan), respectively. Stock-based compensation expense for the nine months ended June 30, 2022 and 2021 was $2,929,279 (including $99,999 for the NoveCite Stock Plan) and $993,114 (including $50,222 for the NoveCite Stock Plan), respectively.
Citius stock plans (in Dollars)							$ 6,261,023										$ 6,261,023
Weighted average period term																	2 years 1 month 6 days
Common shares outstanding																	2,000,000
Stock option plan description																	NoveCite has options outstanding to purchase 2,000,000 common shares at a weighted average exercise price of $0.24 per share, of which 376,665 are exercisable. All of these options vest over 36 months and have a term of 10 years. The weighted average remaining contractual term of options outstanding under the NoveCite Stock Plan is 8.7 years. At June 30, 2022, unrecognized total compensation cost related to unvested awards under the NoveCite Stock Plan of $216,444 is expected to be recognized over a weighted average period of 1.7 years.
Warrants extended term					3 years
Warrants for common stock (in Dollars)					$ 1,294,498
Deemed dividend (in Dollars)																$ 1,450,876	$ 1,450,876
Common Stock [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Issued shares	50,201
Fair value of common stock (in Dollars)	$ 95,884
Shares outstanding							146,129,630									145,979,429	146,129,630	145,979,429	146,129,630	146,029,630	145,979,429		134,701,219	55,576,996		55,576,996
Options to purchase shares			375,000			175,000
Warrants [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Exercise price (in Dollars per share)					$ 1.93
Warrants for common stock (in Dollars)					$ 240,130
Weighted average remaining life of the outstanding warrants							3 years										3 years
Aggregate intrinsic value for the warrants outstanding (in Dollars)																	$ 418,995
Minimum [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Shares of capital stock authorized																						210,000,000
Common shares authorized																						200,000,000
Exercise price (in Dollars per share)							$ 0.9	$ 0.9		$ 1.44	$ 1.44						$ 0.9
Maximum [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Shares of capital stock authorized																						410,000,000
Common shares authorized																						400,000,000
Exercise price (in Dollars per share)							$ 1.47	$ 1.47		$ 1.49	$ 1.49						$ 1.47
Board of Directors [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Options to purchase shares			2,515,000			800,000								125,000
Share price (in Dollars per share)														$ 1.69
Options vest over terms																	10 years
Granted stock options to purchase				100,000
Employees shares				10,000
Consultant shares (in Dollars per share)				$ 2.5
Registered Direct Offering [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock offerings, description													the Company closed a registered direct offering for 50,830,566 common shares and warrants to purchase up to 25,415,283 common shares, at a purchase price of $1.505 per share of common stock and accompanying warrant, for gross proceeds of $76,500,002. The 25,415,283 warrants are immediately exercisable at $1.70 per common share for a term of five years. The Company paid the placement agent a fee of 7% of the gross proceeds totaling $5,355,000 and issued the placement agent 3,558,140 immediately exercisable warrants at $1.881 per common share for a term of five years. The Company also reimbursed the placement agent for $85,000 in expenses and incurred $80,160 in other expenses. Net proceeds from the offering were $70,979,842. The estimated fair value of the 25,415,283 warrants issued to the investors was approximately $42,322,000 and the estimated fair value of the 3,558,140 warrants issued to the placement agent was approximately $5,850,000.
2014 Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock for issuance							866,667										866,667
Shares outstanding							855,171										855,171
2018 Omnibus Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock for issuance																													2,000,000
Number of shares outstanding							1,820,000										1,820,000
2020 Stock Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common shares reserved																												3,110,000
2021 Omnibus Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Option to purchase share outstanding							1,870,000										1,870,000
Remaining shares							1,240,000										1,240,000
2021 Stock Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Issued shares												8,740,000
Shares available for future grants																	3,885,000
Stock Options [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Contractual term																	10 years

Common Stock, Stock Options a_4

Common Stock, Stock Options and Warrants (Details) - Schedule of option activity under the plans	9 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Schedule of option activity under the plans [Abstract]
Option Shares, Outstanding beginning balance | shares	5,755,171
Weighted- Average Exercise Price, Outstanding beginning balance | $ / shares	$ 2.13
Weighted- Average Remaining Contractual Term, Outstanding beginning balance	8 years 7 days
Aggregate Intrinsic Value, Outstanding beginning balance | $	$ 3,589,392
Option Shares, Granted | shares	3,645,000
Weighted- Average Exercise Price, Granted | $ / shares	$ 1.97
Option Shares , Exercised | shares
Weighted- Average Exercise Price, Exercised | $ / shares
Option Shares, Forfeited or expired | shares
Weighted- Average Exercise Price, Forfeited or expired | $ / shares
Option Shares, Outstanding ending balance | shares	9,400,171
Weighted- Average Exercise Price, Outstanding ending balance | $ / shares	$ 2.07
Weighted- Average Remaining Contractual Term, Outstanding ending balance	8 years 21 days
Aggregate Intrinsic Value, Outstanding ending balance | $	$ 302,939
Option Shares, Exercisable | shares	3,675,742
Weighted- Average Exercise Price, Exercisable | $ / shares	$ 2.48
Weighted- Average Remaining Contractual Term, Exercisable	6 years 6 months 21 days
Aggregate Intrinsic Value, Exercisable | $	$ 236,478

Common Stock, Stock Options a_5

Common Stock, Stock Options and Warrants (Details) - Schedule of warrants outstanding	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Number	40,014,418
2017 Public Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.13
Number	1,622,989
Expiration Date	August 8, 2022
2017 Public Offering Underwriter [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.54
Number	65,940
Expiration Date	February 2, 2023
December 2017 Registered Direct/Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.63
Number	640,180
Expiration Date	June 19, 2023
December 2017 Registered Direct/Private Placement Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 5.87
Number	89,625
Expiration Date	December 19, 2022
March 2018 Registered Direct/Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.86
Number	218,972
Expiration Date	October 2, 2023
March 2018 Registered Direct/Private Placement Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.73
Number	46,866
Expiration Date	March 28, 2023
August 2018 Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.15
Number	3,921,569
Expiration Date	August 14, 2023
August 2018 Offering Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.59
Number	189,412
Expiration Date	August 8, 2023
April 2019 Registered Direct/Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.42
Number	1,294,498
Expiration Date	April 5, 2024
April 2019 Registered Direct/Private Placement Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.93
Number	240,130
Expiration Date	April 5, 2024
September 2019 Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 0.77
Number	2,793,297
Expiration Date	September 27, 2024
September 2019 Offering Underwriter [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.12
Number	194,358
Expiration Date	September 27, 2024
February 2020 Exercise Agreement Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.28
Number	138,886
Expiration Date	August 19, 2025
May 2020 Registered Direct Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1
Number	1,670,588
Expiration Date	November 18, 2025
May 2020 Registered Direct Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.33
Number	155,647
Expiration Date	May 14, 2025
August 2020 Underwriter [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.31
Number	201,967
Expiration Date	August 10, 2025
January 2021 Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.23
Number	3,091,192
Expiration Date	July 27, 2026
January 2021 Private Placement Offering Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.62
Number	351,623
Expiration Date	July 27, 2026
February 2021 Registered Direct Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.7
Number	20,580,283
Expiration Date	February 19, 2026
February 2021 Registered Direct Offering Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.88
Number	2,506,396
Expiration Date	February 19, 2026

Common Stock, Stock Options a_6

Common Stock, Stock Options and Warrants (Details) - Schedule of common stock reserved for future issuances	9 Months Ended
	Jun. 30, 2022 shares
Schedule of common stock reserved for future issuances [Abstract]
Stock plan options outstanding	9,400,171
Stock plan shares available for future grants	3,885,000
Warrants outstanding	40,014,418
Total	53,299,589

Related Party Transactions (Det

Related Party Transactions (Details) - Chief Executive Officer [Member]	Apr. 30, 2021 shares
Related Party Transactions (Details) [Line Items]
Term of warrants	3 years
Warrants	1,294,498

Operating Lease (Details)

Operating Lease (Details) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Lease [Abstract]
Lease liability interest expenses	$ 47,881	$ 57,779

Operating Lease (Details) - Sch

Operating Lease (Details) - Schedule operating lease expense - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Lease cost
Operating lease cost	$ 179,116	$ 179,118
Variable lease cost	772	194
Total lease cost	$ 179,888	$ 179,312
Other information
Weighted-average remaining lease term - operating leases	3 years 3 months 18 days	4 years 3 months 18 days
Weighted-average discount rate - operating leases	8%	8%

Operating Lease (Details) - S_2

Operating Lease (Details) - Schedule of lease liabilities due under the company’s non-cancellable leases	Jun. 30, 2022 USD ($)
Schedule of lease liabilities due under the company’s non-cancellable leases [Abstract]
2022 (excluding the 9 months ended June 30, 2022)	$ 60,737
2023	244,165
2024	249,024
2025	253,883
2026	21,460
Total lease payments	829,269
Less: interest	(104,484)
Present value of lease liabilities	$ 724,785

Operating Lease (Details) - S_3

Operating Lease (Details) - Schedule operating leases assets and liabilities - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Assets
Lease asset	$ 691,593	$ 822,828
Total lease assets	691,593	822,828
Liabilities
Current	191,902	177,237
Non-current	532,883	678,234
Total lease liabilities	$ 724,785	$ 855,471